End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
29.06 NZD | +1.79% | -0.31% | +23.14% |
Apr. 09 | New Zealand Shares Fall for Second Day; Fisher & Paykel Healthcare Launches Apnea Mask | MT |
Apr. 09 | Fisher & Paykel Begins Selling Lightest Mask for Sleep Apnea | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- With an expected P/E ratio at 65.83 and 50.72 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+23.14% | 10.17B | B+ | ||
-4.54% | 182B | C+ | ||
+3.39% | 112B | C | ||
-2.28% | 68.58B | A | ||
+5.58% | 51.58B | B- | ||
+7.75% | 44.24B | B- | ||
+9.45% | 43.65B | B+ | ||
+26.34% | 32.46B | B | ||
+20.94% | 25.99B | A- | ||
-0.19% | 25.61B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- FPH Stock
- Ratings Fisher & Paykel Healthcare Corporation Limited